Skip to main content
. 2015 Sep 8;9(Suppl 1):41–49. doi: 10.4137/CCRPM.S23288

Table 2.

Candidate parameters for risk evaluation at baseline and during follow-up periods for RA-ILD patients who are scheduled for biological DMARD therapy.

PARAMETERS HIGH RISK FOR POOR OUTCOMES
Baseline
HRCT pattern UIP pattern
Severity stage III and IV
DLco,% predicted <40% predicted
Extent on HRCT >20%
Follow-up period
SpO2 after six-minute walk or equivalent <90%,
Decrease in FVC ≥10% in absolute value
Decrease in DLco ≥15% in absolute value